Free Trial Information
BioCentury | Jun 4, 2020
Emerging Company Profile

Hayden’s fifth venture, neuro-focused Prilenia, raises $62.5M in Forbion-led A round

...σ1R) - σ non-opioid intracellular receptor 1 SOD1 - Superoxide dismutase 1 VMAT2 (SLC18A2) - Vesicular monoamine transporter...
Read More
BioCentury | Feb 21, 2020
Product Development

Feb. 20 Product Development Quick Takes: Priority Review puts BioMarin on track to score first hemophilia gene therapy approval in U.S.; plus Gilead-CDC, Genfit

...Peroxisome proliferation activated receptor alpha PPARδ - Peroxisome proliferation activated receptor delta VMAT2 (SLC18A2) - Vesicular monoamine transporter...
Read More
BioCentury | Jul 30, 2019
Company News

July 29 Company Quick Takes: Dupixent sales boost Sanofi; plus Twist, J&J, Alkermes and more

Despite multibillion dollar impairment, Sanofi beats on 2Q19 earnings Sanofi (Euronext:SAN; NASDAQ:SNY) reported 2Q19 sales of €496 million from dermatitis and asthma drug Dupixent dupilumab, beating the Street's estimate of €411 million. The pharma also...
Read More
BioCentury | May 3, 2019
Company News

Express Scripts excludes rare disease drugs Onpattro, Ingrezza

Express Scripts excluded from its 2019 preferred formulary two rare disease therapy, Alnylam's amyloidosis drug Onpattro patisiran and Neurocrine's tardive dyskinesia drug Ingrezza valbenazine. Each are one of two approved drugs in their respective indications....
Read More
BioCentury | Jan 5, 2019
Finance

Ready to launch

...primary endpoint in a Phase IIb trial to treat Tourette syndrome. Neurocrine markets the selective vesicular monoamine transporter...
Read More
BioCentury | Dec 14, 2018
Clinical News

Neurocrine's valbenazine misses in Phase IIb for Tourette syndrome

...The company plans to further analyze the data to determine next steps for the selective vesicular monoamine transporter...
...dyskinesia. Neurocrine Biosciences Inc. (NASDAQ:NBIX), San Diego, Calif. Product: Ingrezza valbenazine Business: Neurology Molecular target: Vesicular monoamine transporter...
...at week 12 Status: Phase IIb data Milestone: NA Chris Lieu Ingrezza, valbenazine (MT-5199, NBI-98854, VMAT2) Neurocrine Biosciences Inc. Vesicular monoamine transporter...
Read More
BioCentury | Dec 12, 2018
Clinical News

Neurocrine down on Phase IIb Tourette syndrome miss

...The company plans to further analyze the data to determine next steps for the selective vesicular monoamine transporter...
...in the U.S. to treat adults with tardive dyskinesia. Chris Lieu Ingrezza, valbenazine (MT-5199, NBI-98854, VMAT2) Neurocrine Biosciences Inc. Vesicular monoamine transporter...
Read More
BioCentury | Oct 6, 2018
Finance

Seeking validation

...Phase IIb study of Ingrezza valbenazine to treat pediatric patients with Tourette syndrome. The selective vesicular monoamine transporter...
Read More
BioCentury | Jan 5, 2018
Company News

ICER issues affordability and access alert for tardive dyskinesia drugs

...the benefit provided to patients (see BioCentury Extra, Nov. 21, 2017 ). The drugs are vesicular monoamine transporter...
...Product: Ingrezza valbenazine (MT-5199, NBI-98854); Austedo deutetrabenazine (SD-809) Business: Neurology Alicia Parker Austedo deutetrabenazine Ingrezza MT-5199 NBI-98854 SD-809 valbenazine Neurocrine Biosciences Inc. Teva Pharmaceutical Industries Ltd. Vesicular monoamine transporter...
Read More
BioCentury | Dec 15, 2017
Company News

Teva slashing workforce amid restructuring

...for fremanezumab to prevent migraines. Austedo is a deuterium-substituted analog of tetrabenazine, an inhibitor of vesicular monoamine transporter...
...Aviv: TEVA), Petach Tikva, Israel Business: Other Jennie Walters Austedo fremanezumab Pfizer Inc. Teva Pharmaceutical Industries Ltd. Calcitonin gene-related peptide (CGRP) Vesicular monoamine transporter 2 Vesicular monoamine transporter...
Read More
Items per page:
1 - 10 of 160